IDEAYA Biosciences, Inc. Common Stock
IDYA Real Time Price USDRecent trades of IDYA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IDYA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor Oct. 15, 2024
-
Patent Title: Dihydrothieno[3,2-b]pyridine compounds Feb. 21, 2023
-
Patent Title: Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of ahr Dec. 20, 2022
-
Patent Title: Ahr modulators Aug. 09, 2022
-
Patent Title: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors Sep. 28, 2021
-
Patent Title: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors Aug. 10, 2021
-
Patent Title: 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors Jun. 29, 2021
-
Patent Title: Ahr modulators Oct. 27, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of IDYA in WallStreetBets Daily Discussion
Recent insights relating to IDYA
Recent picks made for IDYA stock on CNBC
ETFs with the largest estimated holdings in IDYA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IDYA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.